Rational combination of <scp>SHP2</scp> and <scp>mTOR</scp> inhibition for the treatment of hepatocellular carcinoma
Antonio Mulero‐Sánchez(Oncode Institute), Sara Mainardi(The Netherlands Cancer Institute), Christel Ramirez(The Netherlands Cancer Institute), René Bernards(The Netherlands Cancer Institute), Astrid Bosma(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Marnix H. P. de Groot(The Netherlands Cancer Institute), Ji‐Ying Song(Oncode Institute), Artur M Burylo(The Netherlands Cancer Institute), Leila Akkari(Oncode Institute), Roderick L. Beijersbergen(The Netherlands Cancer Institute), Cor Lieftink(Cancer Genomics Centre), Hui Wang(Beijing University of Chinese Medicine), Aimée du Chatinier(Princess Máxima Center), Cun Wang(Shanghai Cancer Institute), Sofie J. I. Koomen(The Netherlands Cancer Institute)
Cited by 14
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k